Comparison 5. Three infusions of natalizumab (300 mg) and two infusions of infliximab versus placebo and two infusions of infliximab.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to induce clinical remission at week 10	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.65, 1.24]
2 Failure to induce remission at week 10 in patients with elevated CRP at baseline (posthoc subgroup analysis)	1	35	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.55, 0.97]
3 Adverse events	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.85, 1.03]
4 Withdrawal due to adverse events	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.18 [0.01, 4.18]
5 Serious adverse events	1	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.52 [0.03, 7.98]